http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 15 May 2026 08:30:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/NetworkNews+Audio+Announces+Audio+Press+Release+%28APR%29+Discussing+Overcoming+Limitations+on+First-Generation+GLP-1+Drug+Therapies/26500048.html <p>AUSTIN, Texas, May 15, 2026 (GLOBE NEWSWIRE) -- via <a target="_blank" href="https://www.globenewswire.com/Tracker?data=d76uQX45nh8C77TodhRVkARSMn3rsLtfvi58_WmlHsW4_zoVPZ25lzY5EdGxor2kJEtMrq4vsrdpAPRShl1NNlu7Eal6XcURPAzh7tb4PeM=" rel="nofollow" target="_blank">IBN</a> – NetworkNewsAudio announces the Audio Press Release (APR) titled “The Next Generation of the GLP-1 Revolution Is Already Underway,” featuring <a target="_blank" href="https://www.globenewswire.com/Tracker?data=IMkRZ1V6JKx8G4o0M9GCvkmWsZn5WWzPIt9PDf0oxmCgaOFFIqONMNXQRnoOSLTorCvUd1u_EoSLZbNciJ9XYNXLQNVOPlO4ftnjQoE-505kUAh2al2_wse3kkb-GjOC_ifVSClVA3Cp_HJO7FnvMgSCgZHo_jxZqhcEhQh2ydM=" rel="nofollow" target="_blank">SureNano Science Ltd.</a> (CSE: SURE) (OTCQB: SURNF).</p> <p>To hear the NetworkNewsAudio version, visit: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=m7S12lxfAepKsTt0--2mKPYv8V3xFle9n18gu07jZGYNmtaheR3EIB7MDXoLBe7V8lVr0TSNx6C6wbtacltBpBHzmf43DzB-W2AMUPaYstU=" rel="nofollow" target="_blank">https://nnw.fm/OUoNE</a> </p> <p>To read the original editorial, visit: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=m7S12lxfAepKsTt0--2mKAWOjhW8OBCLd_vZorE9X4eB2Mje08kgoTWAuOs0Gq3G3iRKfWVCTlL3HIr5SOhIvyHIdafC-G3CSyQMZmhoBjU=" rel="nofollow" target="_blank">https://nnw.fm/MTfXm</a></p> <p style="padding-left:40px;">SureNano Science is advancing GEP-44 as a patented, next-generation metabolic therapy intended to improve upon limitations associated with first-generation GLP-1 drugs, positioning this emerging microcap as a minnow among giants quickly transitioning through the FDA http://www.streetinsider.com/Press+Releases/NetworkNews+Audio+Announces+Audio+Press+Release+%28APR%29+Discussing+Overcoming+Limitations+on+First-Generation+GLP-1+Drug+Therapies/26500048.html Fri, 15 May 2026 08:30:00 -0400 O.53179545 SURE SURNF http://www.streetinsider.com/Press+Releases/NetworkNews+Audio+Announces+Audio+Press+Release+%28APR%29+Discussing+Overcoming+Limitations+on+First-Generation+GLP-1+Drug+Therapies/26500048.html <p>AUSTIN, Texas, May 15, 2026 (GLOBE NEWSWIRE) -- via <a target="_blank" href="https://www.globenewswire.com/Tracker?data=d76uQX45nh8C77TodhRVkARSMn3rsLtfvi58_WmlHsW4_zoVPZ25lzY5EdGxor2kJEtMrq4vsrdpAPRShl1NNlu7Eal6XcURPAzh7tb4PeM=" rel="nofollow" target="_blank">IBN</a> – NetworkNewsAudio announces the Audio Press Release (APR) titled “The Next Generation of the GLP-1 Revolution Is Already Underway,” featuring <a target="_blank" href="https://www.globenewswire.com/Tracker?data=IMkRZ1V6JKx8G4o0M9GCvkmWsZn5WWzPIt9PDf0oxmCgaOFFIqONMNXQRnoOSLTorCvUd1u_EoSLZbNciJ9XYNXLQNVOPlO4ftnjQoE-505kUAh2al2_wse3kkb-GjOC_ifVSClVA3Cp_HJO7FnvMgSCgZHo_jxZqhcEhQh2ydM=" rel="nofollow" target="_blank">SureNano Science Ltd.</a> (CSE: SURE) (OTCQB: SURNF).</p> <p>To hear the NetworkNewsAudio version, visit: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=m7S12lxfAepKsTt0--2mKPYv8V3xFle9n18gu07jZGYNmtaheR3EIB7MDXoLBe7V8lVr0TSNx6C6wbtacltBpBHzmf43DzB-W2AMUPaYstU=" rel="nofollow" target="_blank">https://nnw.fm/OUoNE</a> </p> <p>To read the original editorial, visit: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=m7S12lxfAepKsTt0--2mKAWOjhW8OBCLd_vZorE9X4eB2Mje08kgoTWAuOs0Gq3G3iRKfWVCTlL3HIr5SOhIvyHIdafC-G3CSyQMZmhoBjU=" rel="nofollow" target="_blank">https://nnw.fm/MTfXm</a></p> <p style="padding-left:40px;">SureNano Science is advancing GEP-44 as a patented, next-generation metabolic therapy intended to improve upon limitations associated with first-generation GLP-1 drugs, positioning this emerging microcap as a minnow among giants quickly transitioning through the FDA http://www.streetinsider.com/Press+Releases/NetworkNews+Audio+Announces+Audio+Press+Release+%28APR%29+Discussing+Overcoming+Limitations+on+First-Generation+GLP-1+Drug+Therapies/26500048.html Fri, 15 May 2026 08:30:00 -0400 O.53179545 SURE SURNF http://www.streetinsider.com/Press+Releases/NetworkNews+Audio+Announces+Audio+Press+Release+%28APR%29+Discussing+Overcoming+Limitations+on+First-Generation+GLP-1+Drug+Therapies/26500048.html <p>AUSTIN, Texas, May 15, 2026 (GLOBE NEWSWIRE) -- via <a target="_blank" href="https://www.globenewswire.com/Tracker?data=d76uQX45nh8C77TodhRVkARSMn3rsLtfvi58_WmlHsW4_zoVPZ25lzY5EdGxor2kJEtMrq4vsrdpAPRShl1NNlu7Eal6XcURPAzh7tb4PeM=" rel="nofollow" target="_blank">IBN</a> – NetworkNewsAudio announces the Audio Press Release (APR) titled “The Next Generation of the GLP-1 Revolution Is Already Underway,” featuring <a target="_blank" href="https://www.globenewswire.com/Tracker?data=IMkRZ1V6JKx8G4o0M9GCvkmWsZn5WWzPIt9PDf0oxmCgaOFFIqONMNXQRnoOSLTorCvUd1u_EoSLZbNciJ9XYNXLQNVOPlO4ftnjQoE-505kUAh2al2_wse3kkb-GjOC_ifVSClVA3Cp_HJO7FnvMgSCgZHo_jxZqhcEhQh2ydM=" rel="nofollow" target="_blank">SureNano Science Ltd.</a> (CSE: SURE) (OTCQB: SURNF).</p> <p>To hear the NetworkNewsAudio version, visit: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=m7S12lxfAepKsTt0--2mKPYv8V3xFle9n18gu07jZGYNmtaheR3EIB7MDXoLBe7V8lVr0TSNx6C6wbtacltBpBHzmf43DzB-W2AMUPaYstU=" rel="nofollow" target="_blank">https://nnw.fm/OUoNE</a> </p> <p>To read the original editorial, visit: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=m7S12lxfAepKsTt0--2mKAWOjhW8OBCLd_vZorE9X4eB2Mje08kgoTWAuOs0Gq3G3iRKfWVCTlL3HIr5SOhIvyHIdafC-G3CSyQMZmhoBjU=" rel="nofollow" target="_blank">https://nnw.fm/MTfXm</a></p> <p style="padding-left:40px;">SureNano Science is advancing GEP-44 as a patented, next-generation metabolic therapy intended to improve upon limitations associated with first-generation GLP-1 drugs, positioning this emerging microcap as a minnow among giants quickly transitioning through the FDA http://www.streetinsider.com/Press+Releases/NetworkNews+Audio+Announces+Audio+Press+Release+%28APR%29+Discussing+Overcoming+Limitations+on+First-Generation+GLP-1+Drug+Therapies/26500048.html Fri, 15 May 2026 08:30:00 -0400 O.53179545 SURE SURNF http://www.streetinsider.com/Globe+Newswire/NetworkNews+Audio+Announces+Audio+Press+Release+%28APR%29+Discussing+Overcoming+Limitations+on+First-Generation+GLP-1+Drug+Therapies/26500048.html <p>AUSTIN, Texas, May 15, 2026 (GLOBE NEWSWIRE) -- via <a target="_blank" href="https://www.globenewswire.com/Tracker?data=d76uQX45nh8C77TodhRVkARSMn3rsLtfvi58_WmlHsW4_zoVPZ25lzY5EdGxor2kJEtMrq4vsrdpAPRShl1NNlu7Eal6XcURPAzh7tb4PeM=" rel="nofollow" target="_blank">IBN</a> – NetworkNewsAudio announces the Audio Press Release (APR) titled “The Next Generation of the GLP-1 Revolution Is Already Underway,” featuring <a target="_blank" href="https://www.globenewswire.com/Tracker?data=IMkRZ1V6JKx8G4o0M9GCvkmWsZn5WWzPIt9PDf0oxmCgaOFFIqONMNXQRnoOSLTorCvUd1u_EoSLZbNciJ9XYNXLQNVOPlO4ftnjQoE-505kUAh2al2_wse3kkb-GjOC_ifVSClVA3Cp_HJO7FnvMgSCgZHo_jxZqhcEhQh2ydM=" rel="nofollow" target="_blank">SureNano Science Ltd.</a> (CSE: SURE) (OTCQB: SURNF).</p> <p>To hear the NetworkNewsAudio version, visit: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=m7S12lxfAepKsTt0--2mKPYv8V3xFle9n18gu07jZGYNmtaheR3EIB7MDXoLBe7V8lVr0TSNx6C6wbtacltBpBHzmf43DzB-W2AMUPaYstU=" rel="nofollow" target="_blank">https://nnw.fm/OUoNE</a> </p> <p>To read the original editorial, visit: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=m7S12lxfAepKsTt0--2mKAWOjhW8OBCLd_vZorE9X4eB2Mje08kgoTWAuOs0Gq3G3iRKfWVCTlL3HIr5SOhIvyHIdafC-G3CSyQMZmhoBjU=" rel="nofollow" target="_blank">https://nnw.fm/MTfXm</a></p> <p style="padding-left:40px;">SureNano Science is advancing GEP-44 as a patented, next-generation metabolic therapy intended to improve upon limitations associated with first-generation GLP-1 drugs, positioning this emerging microcap as a minnow among giants quickly transitioning through the FDA http://www.streetinsider.com/Globe+Newswire/NetworkNews+Audio+Announces+Audio+Press+Release+%28APR%29+Discussing+Overcoming+Limitations+on+First-Generation+GLP-1+Drug+Therapies/26500048.html Fri, 15 May 2026 08:30:00 -0400 O.53179545 SURE SURNF http://www.streetinsider.com/Globe+Newswire/NetworkNews+Audio+Announces+Audio+Press+Release+%28APR%29+Discussing+Overcoming+Limitations+on+First-Generation+GLP-1+Drug+Therapies/26500048.html <p>AUSTIN, Texas, May 15, 2026 (GLOBE NEWSWIRE) -- via <a target="_blank" href="https://www.globenewswire.com/Tracker?data=d76uQX45nh8C77TodhRVkARSMn3rsLtfvi58_WmlHsW4_zoVPZ25lzY5EdGxor2kJEtMrq4vsrdpAPRShl1NNlu7Eal6XcURPAzh7tb4PeM=" rel="nofollow" target="_blank">IBN</a> – NetworkNewsAudio announces the Audio Press Release (APR) titled “The Next Generation of the GLP-1 Revolution Is Already Underway,” featuring <a target="_blank" href="https://www.globenewswire.com/Tracker?data=IMkRZ1V6JKx8G4o0M9GCvkmWsZn5WWzPIt9PDf0oxmCgaOFFIqONMNXQRnoOSLTorCvUd1u_EoSLZbNciJ9XYNXLQNVOPlO4ftnjQoE-505kUAh2al2_wse3kkb-GjOC_ifVSClVA3Cp_HJO7FnvMgSCgZHo_jxZqhcEhQh2ydM=" rel="nofollow" target="_blank">SureNano Science Ltd.</a> (CSE: SURE) (OTCQB: SURNF).</p> <p>To hear the NetworkNewsAudio version, visit: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=m7S12lxfAepKsTt0--2mKPYv8V3xFle9n18gu07jZGYNmtaheR3EIB7MDXoLBe7V8lVr0TSNx6C6wbtacltBpBHzmf43DzB-W2AMUPaYstU=" rel="nofollow" target="_blank">https://nnw.fm/OUoNE</a> </p> <p>To read the original editorial, visit: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=m7S12lxfAepKsTt0--2mKAWOjhW8OBCLd_vZorE9X4eB2Mje08kgoTWAuOs0Gq3G3iRKfWVCTlL3HIr5SOhIvyHIdafC-G3CSyQMZmhoBjU=" rel="nofollow" target="_blank">https://nnw.fm/MTfXm</a></p> <p style="padding-left:40px;">SureNano Science is advancing GEP-44 as a patented, next-generation metabolic therapy intended to improve upon limitations associated with first-generation GLP-1 drugs, positioning this emerging microcap as a minnow among giants quickly transitioning through the FDA http://www.streetinsider.com/Globe+Newswire/NetworkNews+Audio+Announces+Audio+Press+Release+%28APR%29+Discussing+Overcoming+Limitations+on+First-Generation+GLP-1+Drug+Therapies/26500048.html Fri, 15 May 2026 08:30:00 -0400 O.53179545 SURE SURNF http://www.streetinsider.com/Globe+Newswire/NetworkNews+Audio+Announces+Audio+Press+Release+%28APR%29+Discussing+Overcoming+Limitations+on+First-Generation+GLP-1+Drug+Therapies/26500048.html <p>AUSTIN, Texas, May 15, 2026 (GLOBE NEWSWIRE) -- via <a target="_blank" href="https://www.globenewswire.com/Tracker?data=d76uQX45nh8C77TodhRVkARSMn3rsLtfvi58_WmlHsW4_zoVPZ25lzY5EdGxor2kJEtMrq4vsrdpAPRShl1NNlu7Eal6XcURPAzh7tb4PeM=" rel="nofollow" target="_blank">IBN</a> – NetworkNewsAudio announces the Audio Press Release (APR) titled “The Next Generation of the GLP-1 Revolution Is Already Underway,” featuring <a target="_blank" href="https://www.globenewswire.com/Tracker?data=IMkRZ1V6JKx8G4o0M9GCvkmWsZn5WWzPIt9PDf0oxmCgaOFFIqONMNXQRnoOSLTorCvUd1u_EoSLZbNciJ9XYNXLQNVOPlO4ftnjQoE-505kUAh2al2_wse3kkb-GjOC_ifVSClVA3Cp_HJO7FnvMgSCgZHo_jxZqhcEhQh2ydM=" rel="nofollow" target="_blank">SureNano Science Ltd.</a> (CSE: SURE) (OTCQB: SURNF).</p> <p>To hear the NetworkNewsAudio version, visit: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=m7S12lxfAepKsTt0--2mKPYv8V3xFle9n18gu07jZGYNmtaheR3EIB7MDXoLBe7V8lVr0TSNx6C6wbtacltBpBHzmf43DzB-W2AMUPaYstU=" rel="nofollow" target="_blank">https://nnw.fm/OUoNE</a> </p> <p>To read the original editorial, visit: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=m7S12lxfAepKsTt0--2mKAWOjhW8OBCLd_vZorE9X4eB2Mje08kgoTWAuOs0Gq3G3iRKfWVCTlL3HIr5SOhIvyHIdafC-G3CSyQMZmhoBjU=" rel="nofollow" target="_blank">https://nnw.fm/MTfXm</a></p> <p style="padding-left:40px;">SureNano Science is advancing GEP-44 as a patented, next-generation metabolic therapy intended to improve upon limitations associated with first-generation GLP-1 drugs, positioning this emerging microcap as a minnow among giants quickly transitioning through the FDA http://www.streetinsider.com/Globe+Newswire/NetworkNews+Audio+Announces+Audio+Press+Release+%28APR%29+Discussing+Overcoming+Limitations+on+First-Generation+GLP-1+Drug+Therapies/26500048.html Fri, 15 May 2026 08:30:00 -0400 O.53179545 SURE SURNF http://www.streetinsider.com/Press+Releases/SureNano+Science+Ltd.+%28CSE%3A+SURE%29+%28OTCQB%3A+SURNF%29+Developing+Distinct+Next-Gen+GLP-1+Built+Around+Novel+Peptide/26490609.html <p><i>Disseminated on behalf of </i><a target="_blank" href="https://www.globenewswire.com/Tracker?data=sg9DtVt8PvOkDQ1cxkrXlLZ_nciv8yZiRhNzrxKqc7Ul2hqbHCHaWcfCUsKhOWzwoP9SuR_aeDf8l090dT4K3sY8exXfiz7epmtp2-DPlJh7WvnOuCdFMQ-W_TNbcXTRf9MOfTIw9NIx92NnzS31nYpRp68eteJ9c3oCS5JvYEAMcTQvNZ4CamANFN_Aa1o7" rel="nofollow" target="_blank"><i>SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF)</i></a><i> and may include paid advertising.</i></p> <p><i>NEW YORK, May 14, 2026 (GLOBE NEWSWIRE) -- </i>via <a target="_blank" href="https://www.globenewswire.com/Tracker?data=pbCC0mNabNGq6W-r8nXpeLNwzZ3c-RYQ7VIXzkv_1VwGBqzLQMjG78V2R98WaECHZ5EgVY2A0H01iR6sygdcZg==" rel="nofollow" target="_blank">BioMedWire</a> -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=sg9DtVt8PvOkDQ1cxkrXlLZ_nciv8yZiRhNzrxKqc7XbbPvbGGf6Bn3Dp2Y5K1cz6DUrHI7qzoslBU91G3MHX_iUHW6ywVe6Lm0ujHjH8ZJNC4HcX0bCLV3EQqswHeNR7bWeHy03qkTI4zNgbUNA2y7HFfFh5NPN3hXqSSRDEpg=" rel="nofollow" target="_blank">SureNano Science Ltd.</a> (CSE: SURE) (OTCQB: SURNF) today announces its placement in an editorial published by <a target="_blank" href="https://www.globenewswire.com/Tracker?data=pbCC0mNabNGq6W-r8nXpeBLJ7S-FkOqkz4sHyzt8qAXhNXJhJVqwMHU7Te8sptB2TR15U7xeu1_LS4EVX5PTRA==" rel="nofollow" target="_blank">BioMedWire</a> (BMW), one of 75+ brands within the <a target="_blank" href="https://www.globenewswire.com/Tracker?data=kUTgsvxmkAHfyevvbWxaqgbnCq4Wl1XOrkqX2kHnEsEe3OzeNH2mbus7TMe5tKlHJLdCtLKR-UbyhbWupuULs1Zr5JbJwojIdslGsAjAKfXo0-1B4qNX5A-e3Z7ovZ4942xZVVLRtMgU1ROJx247rA==" rel="nofollow" target="_blank">Dynamic Brand Portfolio</a>@<a target="_blank" href="https://www.globenewswire.com/Tracker?data=ZAbimh84fXkKtfYW4mUxpsLXgovBatuGJwZ3nL65AV3S60IZPcFZsQpxMhbaPm4gTK7z9j0aRtmQBqRx9nhtc12w6vCaJfcrVsqfqXcPRRM=" rel="nofollow" target="_blank">IBN</a> (<a target="_blank" href="https://www.globenewswire.com/Tracker?data=RHM9PFay49SSE-WPWlpjRXJlx6YIT0o4TReXDhSVJTfMGyjeQQHzf-POmuQgMhyYb2aoo9xCh6doPmxWwQfOBk9ZZvmjrbKp1ZzAPXYx5x30375j14xTrKvhP5xWmvX-" rel="nofollow" target="_blank">InvestorBrandNetwork</a>), a specialized communications platform with a focus on financial news and content distribution for private and public companies and the http://www.streetinsider.com/Press+Releases/SureNano+Science+Ltd.+%28CSE%3A+SURE%29+%28OTCQB%3A+SURNF%29+Developing+Distinct+Next-Gen+GLP-1+Built+Around+Novel+Peptide/26490609.html Thu, 14 May 2026 08:30:00 -0400 O.53179545 SURE SURNF http://www.streetinsider.com/Press+Releases/SureNano+Science+Ltd.+%28CSE%3A+SURE%29+%28OTCQB%3A+SURNF%29+Developing+Distinct+Next-Gen+GLP-1+Built+Around+Novel+Peptide/26490609.html <p><i>Disseminated on behalf of </i><a target="_blank" href="https://www.globenewswire.com/Tracker?data=sg9DtVt8PvOkDQ1cxkrXlLZ_nciv8yZiRhNzrxKqc7Ul2hqbHCHaWcfCUsKhOWzwoP9SuR_aeDf8l090dT4K3sY8exXfiz7epmtp2-DPlJh7WvnOuCdFMQ-W_TNbcXTRf9MOfTIw9NIx92NnzS31nYpRp68eteJ9c3oCS5JvYEAMcTQvNZ4CamANFN_Aa1o7" rel="nofollow" target="_blank"><i>SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF)</i></a><i> and may include paid advertising.</i></p> <p><i>NEW YORK, May 14, 2026 (GLOBE NEWSWIRE) -- </i>via <a target="_blank" href="https://www.globenewswire.com/Tracker?data=pbCC0mNabNGq6W-r8nXpeLNwzZ3c-RYQ7VIXzkv_1VwGBqzLQMjG78V2R98WaECHZ5EgVY2A0H01iR6sygdcZg==" rel="nofollow" target="_blank">BioMedWire</a> -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=sg9DtVt8PvOkDQ1cxkrXlLZ_nciv8yZiRhNzrxKqc7XbbPvbGGf6Bn3Dp2Y5K1cz6DUrHI7qzoslBU91G3MHX_iUHW6ywVe6Lm0ujHjH8ZJNC4HcX0bCLV3EQqswHeNR7bWeHy03qkTI4zNgbUNA2y7HFfFh5NPN3hXqSSRDEpg=" rel="nofollow" target="_blank">SureNano Science Ltd.</a> (CSE: SURE) (OTCQB: SURNF) today announces its placement in an editorial published by <a target="_blank" href="https://www.globenewswire.com/Tracker?data=pbCC0mNabNGq6W-r8nXpeBLJ7S-FkOqkz4sHyzt8qAXhNXJhJVqwMHU7Te8sptB2TR15U7xeu1_LS4EVX5PTRA==" rel="nofollow" target="_blank">BioMedWire</a> (BMW), one of 75+ brands within the <a target="_blank" href="https://www.globenewswire.com/Tracker?data=kUTgsvxmkAHfyevvbWxaqgbnCq4Wl1XOrkqX2kHnEsEe3OzeNH2mbus7TMe5tKlHJLdCtLKR-UbyhbWupuULs1Zr5JbJwojIdslGsAjAKfXo0-1B4qNX5A-e3Z7ovZ4942xZVVLRtMgU1ROJx247rA==" rel="nofollow" target="_blank">Dynamic Brand Portfolio</a>@<a target="_blank" href="https://www.globenewswire.com/Tracker?data=ZAbimh84fXkKtfYW4mUxpsLXgovBatuGJwZ3nL65AV3S60IZPcFZsQpxMhbaPm4gTK7z9j0aRtmQBqRx9nhtc12w6vCaJfcrVsqfqXcPRRM=" rel="nofollow" target="_blank">IBN</a> (<a target="_blank" href="https://www.globenewswire.com/Tracker?data=RHM9PFay49SSE-WPWlpjRXJlx6YIT0o4TReXDhSVJTfMGyjeQQHzf-POmuQgMhyYb2aoo9xCh6doPmxWwQfOBk9ZZvmjrbKp1ZzAPXYx5x30375j14xTrKvhP5xWmvX-" rel="nofollow" target="_blank">InvestorBrandNetwork</a>), a specialized communications platform with a focus on financial news and content distribution for private and public companies and the http://www.streetinsider.com/Press+Releases/SureNano+Science+Ltd.+%28CSE%3A+SURE%29+%28OTCQB%3A+SURNF%29+Developing+Distinct+Next-Gen+GLP-1+Built+Around+Novel+Peptide/26490609.html Thu, 14 May 2026 08:30:00 -0400 O.53179545 SURE SURNF http://www.streetinsider.com/Press+Releases/SureNano+Science+Ltd.+%28CSE%3A+SURE%29+%28OTCQB%3A+SURNF%29+Developing+Distinct+Next-Gen+GLP-1+Built+Around+Novel+Peptide/26490609.html <p><i>Disseminated on behalf of </i><a target="_blank" href="https://www.globenewswire.com/Tracker?data=sg9DtVt8PvOkDQ1cxkrXlLZ_nciv8yZiRhNzrxKqc7Ul2hqbHCHaWcfCUsKhOWzwoP9SuR_aeDf8l090dT4K3sY8exXfiz7epmtp2-DPlJh7WvnOuCdFMQ-W_TNbcXTRf9MOfTIw9NIx92NnzS31nYpRp68eteJ9c3oCS5JvYEAMcTQvNZ4CamANFN_Aa1o7" rel="nofollow" target="_blank"><i>SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF)</i></a><i> and may include paid advertising.</i></p> <p><i>NEW YORK, May 14, 2026 (GLOBE NEWSWIRE) -- </i>via <a target="_blank" href="https://www.globenewswire.com/Tracker?data=pbCC0mNabNGq6W-r8nXpeLNwzZ3c-RYQ7VIXzkv_1VwGBqzLQMjG78V2R98WaECHZ5EgVY2A0H01iR6sygdcZg==" rel="nofollow" target="_blank">BioMedWire</a> -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=sg9DtVt8PvOkDQ1cxkrXlLZ_nciv8yZiRhNzrxKqc7XbbPvbGGf6Bn3Dp2Y5K1cz6DUrHI7qzoslBU91G3MHX_iUHW6ywVe6Lm0ujHjH8ZJNC4HcX0bCLV3EQqswHeNR7bWeHy03qkTI4zNgbUNA2y7HFfFh5NPN3hXqSSRDEpg=" rel="nofollow" target="_blank">SureNano Science Ltd.</a> (CSE: SURE) (OTCQB: SURNF) today announces its placement in an editorial published by <a target="_blank" href="https://www.globenewswire.com/Tracker?data=pbCC0mNabNGq6W-r8nXpeBLJ7S-FkOqkz4sHyzt8qAXhNXJhJVqwMHU7Te8sptB2TR15U7xeu1_LS4EVX5PTRA==" rel="nofollow" target="_blank">BioMedWire</a> (BMW), one of 75+ brands within the <a target="_blank" href="https://www.globenewswire.com/Tracker?data=kUTgsvxmkAHfyevvbWxaqgbnCq4Wl1XOrkqX2kHnEsEe3OzeNH2mbus7TMe5tKlHJLdCtLKR-UbyhbWupuULs1Zr5JbJwojIdslGsAjAKfXo0-1B4qNX5A-e3Z7ovZ4942xZVVLRtMgU1ROJx247rA==" rel="nofollow" target="_blank">Dynamic Brand Portfolio</a>@<a target="_blank" href="https://www.globenewswire.com/Tracker?data=ZAbimh84fXkKtfYW4mUxpsLXgovBatuGJwZ3nL65AV3S60IZPcFZsQpxMhbaPm4gTK7z9j0aRtmQBqRx9nhtc12w6vCaJfcrVsqfqXcPRRM=" rel="nofollow" target="_blank">IBN</a> (<a target="_blank" href="https://www.globenewswire.com/Tracker?data=RHM9PFay49SSE-WPWlpjRXJlx6YIT0o4TReXDhSVJTfMGyjeQQHzf-POmuQgMhyYb2aoo9xCh6doPmxWwQfOBk9ZZvmjrbKp1ZzAPXYx5x30375j14xTrKvhP5xWmvX-" rel="nofollow" target="_blank">InvestorBrandNetwork</a>), a specialized communications platform with a focus on financial news and content distribution for private and public companies and the http://www.streetinsider.com/Press+Releases/SureNano+Science+Ltd.+%28CSE%3A+SURE%29+%28OTCQB%3A+SURNF%29+Developing+Distinct+Next-Gen+GLP-1+Built+Around+Novel+Peptide/26490609.html Thu, 14 May 2026 08:30:00 -0400 O.53179545 SURE SURNF http://www.streetinsider.com/Globe+Newswire/SureNano+Science+Ltd.+%28CSE%3A+SURE%29+%28OTCQB%3A+SURNF%29+Developing+Distinct+Next-Gen+GLP-1+Built+Around+Novel+Peptide/26490609.html <p><i>Disseminated on behalf of </i><a target="_blank" href="https://www.globenewswire.com/Tracker?data=sg9DtVt8PvOkDQ1cxkrXlLZ_nciv8yZiRhNzrxKqc7Ul2hqbHCHaWcfCUsKhOWzwoP9SuR_aeDf8l090dT4K3sY8exXfiz7epmtp2-DPlJh7WvnOuCdFMQ-W_TNbcXTRf9MOfTIw9NIx92NnzS31nYpRp68eteJ9c3oCS5JvYEAMcTQvNZ4CamANFN_Aa1o7" rel="nofollow" target="_blank"><i>SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF)</i></a><i> and may include paid advertising.</i></p> <p><i>NEW YORK, May 14, 2026 (GLOBE NEWSWIRE) -- </i>via <a target="_blank" href="https://www.globenewswire.com/Tracker?data=pbCC0mNabNGq6W-r8nXpeLNwzZ3c-RYQ7VIXzkv_1VwGBqzLQMjG78V2R98WaECHZ5EgVY2A0H01iR6sygdcZg==" rel="nofollow" target="_blank">BioMedWire</a> -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=sg9DtVt8PvOkDQ1cxkrXlLZ_nciv8yZiRhNzrxKqc7XbbPvbGGf6Bn3Dp2Y5K1cz6DUrHI7qzoslBU91G3MHX_iUHW6ywVe6Lm0ujHjH8ZJNC4HcX0bCLV3EQqswHeNR7bWeHy03qkTI4zNgbUNA2y7HFfFh5NPN3hXqSSRDEpg=" rel="nofollow" target="_blank">SureNano Science Ltd.</a> (CSE: SURE) (OTCQB: SURNF) today announces its placement in an editorial published by <a target="_blank" href="https://www.globenewswire.com/Tracker?data=pbCC0mNabNGq6W-r8nXpeBLJ7S-FkOqkz4sHyzt8qAXhNXJhJVqwMHU7Te8sptB2TR15U7xeu1_LS4EVX5PTRA==" rel="nofollow" target="_blank">BioMedWire</a> (BMW), one of 75+ brands within the <a target="_blank" href="https://www.globenewswire.com/Tracker?data=kUTgsvxmkAHfyevvbWxaqgbnCq4Wl1XOrkqX2kHnEsEe3OzeNH2mbus7TMe5tKlHJLdCtLKR-UbyhbWupuULs1Zr5JbJwojIdslGsAjAKfXo0-1B4qNX5A-e3Z7ovZ4942xZVVLRtMgU1ROJx247rA==" rel="nofollow" target="_blank">Dynamic Brand Portfolio</a>@<a target="_blank" href="https://www.globenewswire.com/Tracker?data=ZAbimh84fXkKtfYW4mUxpsLXgovBatuGJwZ3nL65AV3S60IZPcFZsQpxMhbaPm4gTK7z9j0aRtmQBqRx9nhtc12w6vCaJfcrVsqfqXcPRRM=" rel="nofollow" target="_blank">IBN</a> (<a target="_blank" href="https://www.globenewswire.com/Tracker?data=RHM9PFay49SSE-WPWlpjRXJlx6YIT0o4TReXDhSVJTfMGyjeQQHzf-POmuQgMhyYb2aoo9xCh6doPmxWwQfOBk9ZZvmjrbKp1ZzAPXYx5x30375j14xTrKvhP5xWmvX-" rel="nofollow" target="_blank">InvestorBrandNetwork</a>), a specialized communications platform with a focus on financial news and content distribution for private and public companies and the http://www.streetinsider.com/Globe+Newswire/SureNano+Science+Ltd.+%28CSE%3A+SURE%29+%28OTCQB%3A+SURNF%29+Developing+Distinct+Next-Gen+GLP-1+Built+Around+Novel+Peptide/26490609.html Thu, 14 May 2026 08:30:00 -0400 O.53179545 SURE SURNF http://www.streetinsider.com/Globe+Newswire/SureNano+Science+Ltd.+%28CSE%3A+SURE%29+%28OTCQB%3A+SURNF%29+Developing+Distinct+Next-Gen+GLP-1+Built+Around+Novel+Peptide/26490609.html <p><i>Disseminated on behalf of </i><a target="_blank" href="https://www.globenewswire.com/Tracker?data=sg9DtVt8PvOkDQ1cxkrXlLZ_nciv8yZiRhNzrxKqc7Ul2hqbHCHaWcfCUsKhOWzwoP9SuR_aeDf8l090dT4K3sY8exXfiz7epmtp2-DPlJh7WvnOuCdFMQ-W_TNbcXTRf9MOfTIw9NIx92NnzS31nYpRp68eteJ9c3oCS5JvYEAMcTQvNZ4CamANFN_Aa1o7" rel="nofollow" target="_blank"><i>SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF)</i></a><i> and may include paid advertising.</i></p> <p><i>NEW YORK, May 14, 2026 (GLOBE NEWSWIRE) -- </i>via <a target="_blank" href="https://www.globenewswire.com/Tracker?data=pbCC0mNabNGq6W-r8nXpeLNwzZ3c-RYQ7VIXzkv_1VwGBqzLQMjG78V2R98WaECHZ5EgVY2A0H01iR6sygdcZg==" rel="nofollow" target="_blank">BioMedWire</a> -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=sg9DtVt8PvOkDQ1cxkrXlLZ_nciv8yZiRhNzrxKqc7XbbPvbGGf6Bn3Dp2Y5K1cz6DUrHI7qzoslBU91G3MHX_iUHW6ywVe6Lm0ujHjH8ZJNC4HcX0bCLV3EQqswHeNR7bWeHy03qkTI4zNgbUNA2y7HFfFh5NPN3hXqSSRDEpg=" rel="nofollow" target="_blank">SureNano Science Ltd.</a> (CSE: SURE) (OTCQB: SURNF) today announces its placement in an editorial published by <a target="_blank" href="https://www.globenewswire.com/Tracker?data=pbCC0mNabNGq6W-r8nXpeBLJ7S-FkOqkz4sHyzt8qAXhNXJhJVqwMHU7Te8sptB2TR15U7xeu1_LS4EVX5PTRA==" rel="nofollow" target="_blank">BioMedWire</a> (BMW), one of 75+ brands within the <a target="_blank" href="https://www.globenewswire.com/Tracker?data=kUTgsvxmkAHfyevvbWxaqgbnCq4Wl1XOrkqX2kHnEsEe3OzeNH2mbus7TMe5tKlHJLdCtLKR-UbyhbWupuULs1Zr5JbJwojIdslGsAjAKfXo0-1B4qNX5A-e3Z7ovZ4942xZVVLRtMgU1ROJx247rA==" rel="nofollow" target="_blank">Dynamic Brand Portfolio</a>@<a target="_blank" href="https://www.globenewswire.com/Tracker?data=ZAbimh84fXkKtfYW4mUxpsLXgovBatuGJwZ3nL65AV3S60IZPcFZsQpxMhbaPm4gTK7z9j0aRtmQBqRx9nhtc12w6vCaJfcrVsqfqXcPRRM=" rel="nofollow" target="_blank">IBN</a> (<a target="_blank" href="https://www.globenewswire.com/Tracker?data=RHM9PFay49SSE-WPWlpjRXJlx6YIT0o4TReXDhSVJTfMGyjeQQHzf-POmuQgMhyYb2aoo9xCh6doPmxWwQfOBk9ZZvmjrbKp1ZzAPXYx5x30375j14xTrKvhP5xWmvX-" rel="nofollow" target="_blank">InvestorBrandNetwork</a>), a specialized communications platform with a focus on financial news and content distribution for private and public companies and the http://www.streetinsider.com/Globe+Newswire/SureNano+Science+Ltd.+%28CSE%3A+SURE%29+%28OTCQB%3A+SURNF%29+Developing+Distinct+Next-Gen+GLP-1+Built+Around+Novel+Peptide/26490609.html Thu, 14 May 2026 08:30:00 -0400 O.53179545 SURE SURNF http://www.streetinsider.com/Globe+Newswire/SureNano+Science+Ltd.+%28CSE%3A+SURE%29+%28OTCQB%3A+SURNF%29+Developing+Distinct+Next-Gen+GLP-1+Built+Around+Novel+Peptide/26490609.html <p><i>Disseminated on behalf of </i><a target="_blank" href="https://www.globenewswire.com/Tracker?data=sg9DtVt8PvOkDQ1cxkrXlLZ_nciv8yZiRhNzrxKqc7Ul2hqbHCHaWcfCUsKhOWzwoP9SuR_aeDf8l090dT4K3sY8exXfiz7epmtp2-DPlJh7WvnOuCdFMQ-W_TNbcXTRf9MOfTIw9NIx92NnzS31nYpRp68eteJ9c3oCS5JvYEAMcTQvNZ4CamANFN_Aa1o7" rel="nofollow" target="_blank"><i>SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF)</i></a><i> and may include paid advertising.</i></p> <p><i>NEW YORK, May 14, 2026 (GLOBE NEWSWIRE) -- </i>via <a target="_blank" href="https://www.globenewswire.com/Tracker?data=pbCC0mNabNGq6W-r8nXpeLNwzZ3c-RYQ7VIXzkv_1VwGBqzLQMjG78V2R98WaECHZ5EgVY2A0H01iR6sygdcZg==" rel="nofollow" target="_blank">BioMedWire</a> -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=sg9DtVt8PvOkDQ1cxkrXlLZ_nciv8yZiRhNzrxKqc7XbbPvbGGf6Bn3Dp2Y5K1cz6DUrHI7qzoslBU91G3MHX_iUHW6ywVe6Lm0ujHjH8ZJNC4HcX0bCLV3EQqswHeNR7bWeHy03qkTI4zNgbUNA2y7HFfFh5NPN3hXqSSRDEpg=" rel="nofollow" target="_blank">SureNano Science Ltd.</a> (CSE: SURE) (OTCQB: SURNF) today announces its placement in an editorial published by <a target="_blank" href="https://www.globenewswire.com/Tracker?data=pbCC0mNabNGq6W-r8nXpeBLJ7S-FkOqkz4sHyzt8qAXhNXJhJVqwMHU7Te8sptB2TR15U7xeu1_LS4EVX5PTRA==" rel="nofollow" target="_blank">BioMedWire</a> (BMW), one of 75+ brands within the <a target="_blank" href="https://www.globenewswire.com/Tracker?data=kUTgsvxmkAHfyevvbWxaqgbnCq4Wl1XOrkqX2kHnEsEe3OzeNH2mbus7TMe5tKlHJLdCtLKR-UbyhbWupuULs1Zr5JbJwojIdslGsAjAKfXo0-1B4qNX5A-e3Z7ovZ4942xZVVLRtMgU1ROJx247rA==" rel="nofollow" target="_blank">Dynamic Brand Portfolio</a>@<a target="_blank" href="https://www.globenewswire.com/Tracker?data=ZAbimh84fXkKtfYW4mUxpsLXgovBatuGJwZ3nL65AV3S60IZPcFZsQpxMhbaPm4gTK7z9j0aRtmQBqRx9nhtc12w6vCaJfcrVsqfqXcPRRM=" rel="nofollow" target="_blank">IBN</a> (<a target="_blank" href="https://www.globenewswire.com/Tracker?data=RHM9PFay49SSE-WPWlpjRXJlx6YIT0o4TReXDhSVJTfMGyjeQQHzf-POmuQgMhyYb2aoo9xCh6doPmxWwQfOBk9ZZvmjrbKp1ZzAPXYx5x30375j14xTrKvhP5xWmvX-" rel="nofollow" target="_blank">InvestorBrandNetwork</a>), a specialized communications platform with a focus on financial news and content distribution for private and public companies and the http://www.streetinsider.com/Globe+Newswire/SureNano+Science+Ltd.+%28CSE%3A+SURE%29+%28OTCQB%3A+SURNF%29+Developing+Distinct+Next-Gen+GLP-1+Built+Around+Novel+Peptide/26490609.html Thu, 14 May 2026 08:30:00 -0400 O.53179545 SURE SURNF http://www.streetinsider.com/Press+Releases/SureNano+Science+Ltd.+%28CSE%3A+SURE%29+%28OTCQB%3A+SURNF%29+Advancing+a+Differentiated+Next-Gen+GLP-1+Platform/26473690.html <p><i>Disseminated on behalf of </i><a target="_blank" href="https://www.globenewswire.com/Tracker?data=ZMsYJktRaz5Gr5MKGhdwMTNPZ2kUbvDG558fLgq7PkgK-sNhsBEGqgnaMtZSEKlS2TRlu0PdGX21xVmSZdR5wex_hKbkeG3NXtgYfIbYgELLOxpYlzdxXZGQcbSKF8PvwVBoM1g0Il01Ui0fN_621O6_eiQtPBCT4-Y1jiB8e4AG1bhmC4HjOPdwgx4BE2g8" rel="nofollow" target="_blank"><i>SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF)</i></a><i> and may include paid advertising.</i></p> <p>NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- via <a target="_blank" href="https://www.globenewswire.com/Tracker?data=jFP991va0M3PS5CuMLWpCXsjx4N-MPG-GIAs9UBgCiGvioZHSdtMUz_pbUt-PbC1MGjvZtMw0GYuRwK_lvBqcA==" rel="nofollow" target="_blank">BioMedWire</a> -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=ZMsYJktRaz5Gr5MKGhdwMTNPZ2kUbvDG558fLgq7Pkj2qRHTEzp4THOrDOmTRhufQ6XHDf2qBORvCaYH2yneI67HuCKLFxXbcJgmSn0pr9hq9MiOrdzOdTUjTPpQnVq6Zd1h9m-bgMtE892aL7ZB_pxDJwto85jR8LRZjIp7QzY=" rel="nofollow" target="_blank">SureNano Science Ltd.</a> (CSE: SURE) (OTCQB: SURNF) today announces its placement in an editorial published by <a target="_blank" href="https://www.globenewswire.com/Tracker?data=jFP991va0M3PS5CuMLWpCcU2LVi27hfcOY2mbXMjx7GwVQaaG6VQfTjvcZZMLanK6kHvYiw3es28aTxhK3cH7Q==" rel="nofollow" target="_blank">BioMedWire</a> (BMW), one of 75+ brands within the <a target="_blank" href="https://www.globenewswire.com/Tracker?data=FctJWDG_QcBLsdx0qnkcXqzWKxXZkKLrY-MkOx0pYqj-gww-CFgB9JYU9P2vZYaSnX2aqr6LAGFbdul7KmLTCY1P22vq6GTH3FscSaJ8FbiHT5uUjzz15FbPyzHeRtfyoE2R6i2flePYEAHwVVCvOQ==" rel="nofollow" target="_blank">Dynamic Brand Portfolio</a>@<a target="_blank" href="https://www.globenewswire.com/Tracker?data=4nAXK5xf_68cU_4QKOg17OFGPlxqS4PXlPZnr0Yqwcry_OgBWfB1gE9r_zTAtlT-qu8ySMzzsriOAsyr53uNSeRvvyK1P0ztNq4f55Nw5ZE=" rel="nofollow" target="_blank">IBN</a> (<a target="_blank" href="https://www.globenewswire.com/Tracker?data=MCHwEu46nLpZgHT_nxLpHgEUk7B3pr6AQwnePAW7_GYMCeyn_wpKmbAozCT5E1iBclVEMZUEm7oGjKl-oNF891uFdT6kz8msEZWo0T4MuRGTjzVjRoEkPi1BOKakQSPj" rel="nofollow" target="_blank">InvestorBrandNetwork</a>), a specialized communications platform with a focus on financial news and content distribution for private and public companies and http://www.streetinsider.com/Press+Releases/SureNano+Science+Ltd.+%28CSE%3A+SURE%29+%28OTCQB%3A+SURNF%29+Advancing+a+Differentiated+Next-Gen+GLP-1+Platform/26473690.html Tue, 12 May 2026 08:30:00 -0400 O.53179545 SURE SURNF http://www.streetinsider.com/Press+Releases/SureNano+Science+Ltd.+%28CSE%3A+SURE%29+%28OTCQB%3A+SURNF%29+Advancing+a+Differentiated+Next-Gen+GLP-1+Platform/26473690.html <p><i>Disseminated on behalf of </i><a target="_blank" href="https://www.globenewswire.com/Tracker?data=ZMsYJktRaz5Gr5MKGhdwMTNPZ2kUbvDG558fLgq7PkgK-sNhsBEGqgnaMtZSEKlS2TRlu0PdGX21xVmSZdR5wex_hKbkeG3NXtgYfIbYgELLOxpYlzdxXZGQcbSKF8PvwVBoM1g0Il01Ui0fN_621O6_eiQtPBCT4-Y1jiB8e4AG1bhmC4HjOPdwgx4BE2g8" rel="nofollow" target="_blank"><i>SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF)</i></a><i> and may include paid advertising.</i></p> <p>NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- via <a target="_blank" href="https://www.globenewswire.com/Tracker?data=jFP991va0M3PS5CuMLWpCXsjx4N-MPG-GIAs9UBgCiGvioZHSdtMUz_pbUt-PbC1MGjvZtMw0GYuRwK_lvBqcA==" rel="nofollow" target="_blank">BioMedWire</a> -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=ZMsYJktRaz5Gr5MKGhdwMTNPZ2kUbvDG558fLgq7Pkj2qRHTEzp4THOrDOmTRhufQ6XHDf2qBORvCaYH2yneI67HuCKLFxXbcJgmSn0pr9hq9MiOrdzOdTUjTPpQnVq6Zd1h9m-bgMtE892aL7ZB_pxDJwto85jR8LRZjIp7QzY=" rel="nofollow" target="_blank">SureNano Science Ltd.</a> (CSE: SURE) (OTCQB: SURNF) today announces its placement in an editorial published by <a target="_blank" href="https://www.globenewswire.com/Tracker?data=jFP991va0M3PS5CuMLWpCcU2LVi27hfcOY2mbXMjx7GwVQaaG6VQfTjvcZZMLanK6kHvYiw3es28aTxhK3cH7Q==" rel="nofollow" target="_blank">BioMedWire</a> (BMW), one of 75+ brands within the <a target="_blank" href="https://www.globenewswire.com/Tracker?data=FctJWDG_QcBLsdx0qnkcXqzWKxXZkKLrY-MkOx0pYqj-gww-CFgB9JYU9P2vZYaSnX2aqr6LAGFbdul7KmLTCY1P22vq6GTH3FscSaJ8FbiHT5uUjzz15FbPyzHeRtfyoE2R6i2flePYEAHwVVCvOQ==" rel="nofollow" target="_blank">Dynamic Brand Portfolio</a>@<a target="_blank" href="https://www.globenewswire.com/Tracker?data=4nAXK5xf_68cU_4QKOg17OFGPlxqS4PXlPZnr0Yqwcry_OgBWfB1gE9r_zTAtlT-qu8ySMzzsriOAsyr53uNSeRvvyK1P0ztNq4f55Nw5ZE=" rel="nofollow" target="_blank">IBN</a> (<a target="_blank" href="https://www.globenewswire.com/Tracker?data=MCHwEu46nLpZgHT_nxLpHgEUk7B3pr6AQwnePAW7_GYMCeyn_wpKmbAozCT5E1iBclVEMZUEm7oGjKl-oNF891uFdT6kz8msEZWo0T4MuRGTjzVjRoEkPi1BOKakQSPj" rel="nofollow" target="_blank">InvestorBrandNetwork</a>), a specialized communications platform with a focus on financial news and content distribution for private and public companies and http://www.streetinsider.com/Press+Releases/SureNano+Science+Ltd.+%28CSE%3A+SURE%29+%28OTCQB%3A+SURNF%29+Advancing+a+Differentiated+Next-Gen+GLP-1+Platform/26473690.html Tue, 12 May 2026 08:30:00 -0400 O.53179545 SURE SURNF http://www.streetinsider.com/Press+Releases/SureNano+Science+Ltd.+%28CSE%3A+SURE%29+%28OTCQB%3A+SURNF%29+Advancing+a+Differentiated+Next-Gen+GLP-1+Platform/26473690.html <p><i>Disseminated on behalf of </i><a target="_blank" href="https://www.globenewswire.com/Tracker?data=ZMsYJktRaz5Gr5MKGhdwMTNPZ2kUbvDG558fLgq7PkgK-sNhsBEGqgnaMtZSEKlS2TRlu0PdGX21xVmSZdR5wex_hKbkeG3NXtgYfIbYgELLOxpYlzdxXZGQcbSKF8PvwVBoM1g0Il01Ui0fN_621O6_eiQtPBCT4-Y1jiB8e4AG1bhmC4HjOPdwgx4BE2g8" rel="nofollow" target="_blank"><i>SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF)</i></a><i> and may include paid advertising.</i></p> <p>NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- via <a target="_blank" href="https://www.globenewswire.com/Tracker?data=jFP991va0M3PS5CuMLWpCXsjx4N-MPG-GIAs9UBgCiGvioZHSdtMUz_pbUt-PbC1MGjvZtMw0GYuRwK_lvBqcA==" rel="nofollow" target="_blank">BioMedWire</a> -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=ZMsYJktRaz5Gr5MKGhdwMTNPZ2kUbvDG558fLgq7Pkj2qRHTEzp4THOrDOmTRhufQ6XHDf2qBORvCaYH2yneI67HuCKLFxXbcJgmSn0pr9hq9MiOrdzOdTUjTPpQnVq6Zd1h9m-bgMtE892aL7ZB_pxDJwto85jR8LRZjIp7QzY=" rel="nofollow" target="_blank">SureNano Science Ltd.</a> (CSE: SURE) (OTCQB: SURNF) today announces its placement in an editorial published by <a target="_blank" href="https://www.globenewswire.com/Tracker?data=jFP991va0M3PS5CuMLWpCcU2LVi27hfcOY2mbXMjx7GwVQaaG6VQfTjvcZZMLanK6kHvYiw3es28aTxhK3cH7Q==" rel="nofollow" target="_blank">BioMedWire</a> (BMW), one of 75+ brands within the <a target="_blank" href="https://www.globenewswire.com/Tracker?data=FctJWDG_QcBLsdx0qnkcXqzWKxXZkKLrY-MkOx0pYqj-gww-CFgB9JYU9P2vZYaSnX2aqr6LAGFbdul7KmLTCY1P22vq6GTH3FscSaJ8FbiHT5uUjzz15FbPyzHeRtfyoE2R6i2flePYEAHwVVCvOQ==" rel="nofollow" target="_blank">Dynamic Brand Portfolio</a>@<a target="_blank" href="https://www.globenewswire.com/Tracker?data=4nAXK5xf_68cU_4QKOg17OFGPlxqS4PXlPZnr0Yqwcry_OgBWfB1gE9r_zTAtlT-qu8ySMzzsriOAsyr53uNSeRvvyK1P0ztNq4f55Nw5ZE=" rel="nofollow" target="_blank">IBN</a> (<a target="_blank" href="https://www.globenewswire.com/Tracker?data=MCHwEu46nLpZgHT_nxLpHgEUk7B3pr6AQwnePAW7_GYMCeyn_wpKmbAozCT5E1iBclVEMZUEm7oGjKl-oNF891uFdT6kz8msEZWo0T4MuRGTjzVjRoEkPi1BOKakQSPj" rel="nofollow" target="_blank">InvestorBrandNetwork</a>), a specialized communications platform with a focus on financial news and content distribution for private and public companies and http://www.streetinsider.com/Press+Releases/SureNano+Science+Ltd.+%28CSE%3A+SURE%29+%28OTCQB%3A+SURNF%29+Advancing+a+Differentiated+Next-Gen+GLP-1+Platform/26473690.html Tue, 12 May 2026 08:30:00 -0400 O.53179545 SURE SURNF http://www.streetinsider.com/Globe+Newswire/SureNano+Science+Ltd.+%28CSE%3A+SURE%29+%28OTCQB%3A+SURNF%29+Advancing+a+Differentiated+Next-Gen+GLP-1+Platform/26473690.html <p><i>Disseminated on behalf of </i><a target="_blank" href="https://www.globenewswire.com/Tracker?data=ZMsYJktRaz5Gr5MKGhdwMTNPZ2kUbvDG558fLgq7PkgK-sNhsBEGqgnaMtZSEKlS2TRlu0PdGX21xVmSZdR5wex_hKbkeG3NXtgYfIbYgELLOxpYlzdxXZGQcbSKF8PvwVBoM1g0Il01Ui0fN_621O6_eiQtPBCT4-Y1jiB8e4AG1bhmC4HjOPdwgx4BE2g8" rel="nofollow" target="_blank"><i>SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF)</i></a><i> and may include paid advertising.</i></p> <p>NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- via <a target="_blank" href="https://www.globenewswire.com/Tracker?data=jFP991va0M3PS5CuMLWpCXsjx4N-MPG-GIAs9UBgCiGvioZHSdtMUz_pbUt-PbC1MGjvZtMw0GYuRwK_lvBqcA==" rel="nofollow" target="_blank">BioMedWire</a> -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=ZMsYJktRaz5Gr5MKGhdwMTNPZ2kUbvDG558fLgq7Pkj2qRHTEzp4THOrDOmTRhufQ6XHDf2qBORvCaYH2yneI67HuCKLFxXbcJgmSn0pr9hq9MiOrdzOdTUjTPpQnVq6Zd1h9m-bgMtE892aL7ZB_pxDJwto85jR8LRZjIp7QzY=" rel="nofollow" target="_blank">SureNano Science Ltd.</a> (CSE: SURE) (OTCQB: SURNF) today announces its placement in an editorial published by <a target="_blank" href="https://www.globenewswire.com/Tracker?data=jFP991va0M3PS5CuMLWpCcU2LVi27hfcOY2mbXMjx7GwVQaaG6VQfTjvcZZMLanK6kHvYiw3es28aTxhK3cH7Q==" rel="nofollow" target="_blank">BioMedWire</a> (BMW), one of 75+ brands within the <a target="_blank" href="https://www.globenewswire.com/Tracker?data=FctJWDG_QcBLsdx0qnkcXqzWKxXZkKLrY-MkOx0pYqj-gww-CFgB9JYU9P2vZYaSnX2aqr6LAGFbdul7KmLTCY1P22vq6GTH3FscSaJ8FbiHT5uUjzz15FbPyzHeRtfyoE2R6i2flePYEAHwVVCvOQ==" rel="nofollow" target="_blank">Dynamic Brand Portfolio</a>@<a target="_blank" href="https://www.globenewswire.com/Tracker?data=4nAXK5xf_68cU_4QKOg17OFGPlxqS4PXlPZnr0Yqwcry_OgBWfB1gE9r_zTAtlT-qu8ySMzzsriOAsyr53uNSeRvvyK1P0ztNq4f55Nw5ZE=" rel="nofollow" target="_blank">IBN</a> (<a target="_blank" href="https://www.globenewswire.com/Tracker?data=MCHwEu46nLpZgHT_nxLpHgEUk7B3pr6AQwnePAW7_GYMCeyn_wpKmbAozCT5E1iBclVEMZUEm7oGjKl-oNF891uFdT6kz8msEZWo0T4MuRGTjzVjRoEkPi1BOKakQSPj" rel="nofollow" target="_blank">InvestorBrandNetwork</a>), a specialized communications platform with a focus on financial news and content distribution for private and public companies and http://www.streetinsider.com/Globe+Newswire/SureNano+Science+Ltd.+%28CSE%3A+SURE%29+%28OTCQB%3A+SURNF%29+Advancing+a+Differentiated+Next-Gen+GLP-1+Platform/26473690.html Tue, 12 May 2026 08:30:00 -0400 O.53179545 SURE SURNF http://www.streetinsider.com/Globe+Newswire/SureNano+Science+Ltd.+%28CSE%3A+SURE%29+%28OTCQB%3A+SURNF%29+Advancing+a+Differentiated+Next-Gen+GLP-1+Platform/26473690.html <p><i>Disseminated on behalf of </i><a target="_blank" href="https://www.globenewswire.com/Tracker?data=ZMsYJktRaz5Gr5MKGhdwMTNPZ2kUbvDG558fLgq7PkgK-sNhsBEGqgnaMtZSEKlS2TRlu0PdGX21xVmSZdR5wex_hKbkeG3NXtgYfIbYgELLOxpYlzdxXZGQcbSKF8PvwVBoM1g0Il01Ui0fN_621O6_eiQtPBCT4-Y1jiB8e4AG1bhmC4HjOPdwgx4BE2g8" rel="nofollow" target="_blank"><i>SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF)</i></a><i> and may include paid advertising.</i></p> <p>NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- via <a target="_blank" href="https://www.globenewswire.com/Tracker?data=jFP991va0M3PS5CuMLWpCXsjx4N-MPG-GIAs9UBgCiGvioZHSdtMUz_pbUt-PbC1MGjvZtMw0GYuRwK_lvBqcA==" rel="nofollow" target="_blank">BioMedWire</a> -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=ZMsYJktRaz5Gr5MKGhdwMTNPZ2kUbvDG558fLgq7Pkj2qRHTEzp4THOrDOmTRhufQ6XHDf2qBORvCaYH2yneI67HuCKLFxXbcJgmSn0pr9hq9MiOrdzOdTUjTPpQnVq6Zd1h9m-bgMtE892aL7ZB_pxDJwto85jR8LRZjIp7QzY=" rel="nofollow" target="_blank">SureNano Science Ltd.</a> (CSE: SURE) (OTCQB: SURNF) today announces its placement in an editorial published by <a target="_blank" href="https://www.globenewswire.com/Tracker?data=jFP991va0M3PS5CuMLWpCcU2LVi27hfcOY2mbXMjx7GwVQaaG6VQfTjvcZZMLanK6kHvYiw3es28aTxhK3cH7Q==" rel="nofollow" target="_blank">BioMedWire</a> (BMW), one of 75+ brands within the <a target="_blank" href="https://www.globenewswire.com/Tracker?data=FctJWDG_QcBLsdx0qnkcXqzWKxXZkKLrY-MkOx0pYqj-gww-CFgB9JYU9P2vZYaSnX2aqr6LAGFbdul7KmLTCY1P22vq6GTH3FscSaJ8FbiHT5uUjzz15FbPyzHeRtfyoE2R6i2flePYEAHwVVCvOQ==" rel="nofollow" target="_blank">Dynamic Brand Portfolio</a>@<a target="_blank" href="https://www.globenewswire.com/Tracker?data=4nAXK5xf_68cU_4QKOg17OFGPlxqS4PXlPZnr0Yqwcry_OgBWfB1gE9r_zTAtlT-qu8ySMzzsriOAsyr53uNSeRvvyK1P0ztNq4f55Nw5ZE=" rel="nofollow" target="_blank">IBN</a> (<a target="_blank" href="https://www.globenewswire.com/Tracker?data=MCHwEu46nLpZgHT_nxLpHgEUk7B3pr6AQwnePAW7_GYMCeyn_wpKmbAozCT5E1iBclVEMZUEm7oGjKl-oNF891uFdT6kz8msEZWo0T4MuRGTjzVjRoEkPi1BOKakQSPj" rel="nofollow" target="_blank">InvestorBrandNetwork</a>), a specialized communications platform with a focus on financial news and content distribution for private and public companies and http://www.streetinsider.com/Globe+Newswire/SureNano+Science+Ltd.+%28CSE%3A+SURE%29+%28OTCQB%3A+SURNF%29+Advancing+a+Differentiated+Next-Gen+GLP-1+Platform/26473690.html Tue, 12 May 2026 08:30:00 -0400 O.53179545 SURE SURNF http://www.streetinsider.com/Globe+Newswire/SureNano+Science+Ltd.+%28CSE%3A+SURE%29+%28OTCQB%3A+SURNF%29+Advancing+a+Differentiated+Next-Gen+GLP-1+Platform/26473690.html <p><i>Disseminated on behalf of </i><a target="_blank" href="https://www.globenewswire.com/Tracker?data=ZMsYJktRaz5Gr5MKGhdwMTNPZ2kUbvDG558fLgq7PkgK-sNhsBEGqgnaMtZSEKlS2TRlu0PdGX21xVmSZdR5wex_hKbkeG3NXtgYfIbYgELLOxpYlzdxXZGQcbSKF8PvwVBoM1g0Il01Ui0fN_621O6_eiQtPBCT4-Y1jiB8e4AG1bhmC4HjOPdwgx4BE2g8" rel="nofollow" target="_blank"><i>SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF)</i></a><i> and may include paid advertising.</i></p> <p>NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- via <a target="_blank" href="https://www.globenewswire.com/Tracker?data=jFP991va0M3PS5CuMLWpCXsjx4N-MPG-GIAs9UBgCiGvioZHSdtMUz_pbUt-PbC1MGjvZtMw0GYuRwK_lvBqcA==" rel="nofollow" target="_blank">BioMedWire</a> -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=ZMsYJktRaz5Gr5MKGhdwMTNPZ2kUbvDG558fLgq7Pkj2qRHTEzp4THOrDOmTRhufQ6XHDf2qBORvCaYH2yneI67HuCKLFxXbcJgmSn0pr9hq9MiOrdzOdTUjTPpQnVq6Zd1h9m-bgMtE892aL7ZB_pxDJwto85jR8LRZjIp7QzY=" rel="nofollow" target="_blank">SureNano Science Ltd.</a> (CSE: SURE) (OTCQB: SURNF) today announces its placement in an editorial published by <a target="_blank" href="https://www.globenewswire.com/Tracker?data=jFP991va0M3PS5CuMLWpCcU2LVi27hfcOY2mbXMjx7GwVQaaG6VQfTjvcZZMLanK6kHvYiw3es28aTxhK3cH7Q==" rel="nofollow" target="_blank">BioMedWire</a> (BMW), one of 75+ brands within the <a target="_blank" href="https://www.globenewswire.com/Tracker?data=FctJWDG_QcBLsdx0qnkcXqzWKxXZkKLrY-MkOx0pYqj-gww-CFgB9JYU9P2vZYaSnX2aqr6LAGFbdul7KmLTCY1P22vq6GTH3FscSaJ8FbiHT5uUjzz15FbPyzHeRtfyoE2R6i2flePYEAHwVVCvOQ==" rel="nofollow" target="_blank">Dynamic Brand Portfolio</a>@<a target="_blank" href="https://www.globenewswire.com/Tracker?data=4nAXK5xf_68cU_4QKOg17OFGPlxqS4PXlPZnr0Yqwcry_OgBWfB1gE9r_zTAtlT-qu8ySMzzsriOAsyr53uNSeRvvyK1P0ztNq4f55Nw5ZE=" rel="nofollow" target="_blank">IBN</a> (<a target="_blank" href="https://www.globenewswire.com/Tracker?data=MCHwEu46nLpZgHT_nxLpHgEUk7B3pr6AQwnePAW7_GYMCeyn_wpKmbAozCT5E1iBclVEMZUEm7oGjKl-oNF891uFdT6kz8msEZWo0T4MuRGTjzVjRoEkPi1BOKakQSPj" rel="nofollow" target="_blank">InvestorBrandNetwork</a>), a specialized communications platform with a focus on financial news and content distribution for private and public companies and http://www.streetinsider.com/Globe+Newswire/SureNano+Science+Ltd.+%28CSE%3A+SURE%29+%28OTCQB%3A+SURNF%29+Advancing+a+Differentiated+Next-Gen+GLP-1+Platform/26473690.html Tue, 12 May 2026 08:30:00 -0400 O.53179545 SURE SURNF http://www.streetinsider.com/Press+Releases/The+Next+Generation+of+the+GLP-1+Revolution+Is+Already+Underway/26465701.html <p>AUSTIN, Texas, May 11, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=447VppT4EXxq_CCLB-sZm4HI-4KfxnaBb_V7jK4mVgmGT9tfMoQV3ndYuiNHZSq62npUt-qcWMUO0BJ2Xmr5OXNkNo1qhbJrjYlg6QNqLhuAm6eUoS5DZ0bZLasNuorJ" rel="nofollow" target="_blank">BioMedWire Editorial Coverage</a>: Obesity and type 2 diabetes mellitus (T2DM) have become two of the most pressing healthcare challenges worldwide, driving rising rates of cardiovascular disease, fatty liver disease, kidney complications and escalating healthcare costs. What began as a niche class of diabetes medications has evolved into one of the most transformative therapeutic categories in modern medicine, with GLP-1 receptor agonists now reshaping obesity treatment, metabolic care and potentially even neurodegenerative disease management. Against this backdrop, <strong>SureNano Science Ltd.</strong> (CSE: SURE) (OTCQB: SURNF), (<a target="_blank" href="https://www.globenewswire.com/Tracker?data=TxIEcDI7YtwQSV7h41tMHH-Mi0jMbk21NwO5mbPpRIYxKphxg9hCiTXtPNdnIHiGKdtrmEQHPZ4F3mIj7ci4n-EhpMw_js6g6yU0kaihYelzhgCBhtaOTXgXjyQEGBKEXpqtESvHgh35SZCZnFLCBA==" rel="nofollow" http://www.streetinsider.com/Press+Releases/The+Next+Generation+of+the+GLP-1+Revolution+Is+Already+Underway/26465701.html Mon, 11 May 2026 08:30:00 -0400 A.02973684 A.06822034 A.50200193 AMGN LLY NOVOB NVO O.00000313 O.00027089 O.00285735 O.00291573 O.00448140 O.03044482 O.20026344 O.53179545 PFE SURE SURNF http://www.streetinsider.com/Press+Releases/The+Next+Generation+of+the+GLP-1+Revolution+Is+Already+Underway/26465701.html <p>AUSTIN, Texas, May 11, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=447VppT4EXxq_CCLB-sZm4HI-4KfxnaBb_V7jK4mVgmGT9tfMoQV3ndYuiNHZSq62npUt-qcWMUO0BJ2Xmr5OXNkNo1qhbJrjYlg6QNqLhuAm6eUoS5DZ0bZLasNuorJ" rel="nofollow" target="_blank">BioMedWire Editorial Coverage</a>: Obesity and type 2 diabetes mellitus (T2DM) have become two of the most pressing healthcare challenges worldwide, driving rising rates of cardiovascular disease, fatty liver disease, kidney complications and escalating healthcare costs. What began as a niche class of diabetes medications has evolved into one of the most transformative therapeutic categories in modern medicine, with GLP-1 receptor agonists now reshaping obesity treatment, metabolic care and potentially even neurodegenerative disease management. Against this backdrop, <strong>SureNano Science Ltd.</strong> (CSE: SURE) (OTCQB: SURNF), (<a target="_blank" href="https://www.globenewswire.com/Tracker?data=TxIEcDI7YtwQSV7h41tMHH-Mi0jMbk21NwO5mbPpRIYxKphxg9hCiTXtPNdnIHiGKdtrmEQHPZ4F3mIj7ci4n-EhpMw_js6g6yU0kaihYelzhgCBhtaOTXgXjyQEGBKEXpqtESvHgh35SZCZnFLCBA==" rel="nofollow" http://www.streetinsider.com/Press+Releases/The+Next+Generation+of+the+GLP-1+Revolution+Is+Already+Underway/26465701.html Mon, 11 May 2026 08:30:00 -0400 A.02973684 A.06822034 A.50200193 AMGN LLY NOVOB NVO O.00000313 O.00027089 O.00285735 O.00291573 O.00448140 O.03044482 O.20026344 O.53179545 PFE SURE SURNF http://www.streetinsider.com/Press+Releases/The+Next+Generation+of+the+GLP-1+Revolution+Is+Already+Underway/26465701.html <p>AUSTIN, Texas, May 11, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=447VppT4EXxq_CCLB-sZm4HI-4KfxnaBb_V7jK4mVgmGT9tfMoQV3ndYuiNHZSq62npUt-qcWMUO0BJ2Xmr5OXNkNo1qhbJrjYlg6QNqLhuAm6eUoS5DZ0bZLasNuorJ" rel="nofollow" target="_blank">BioMedWire Editorial Coverage</a>: Obesity and type 2 diabetes mellitus (T2DM) have become two of the most pressing healthcare challenges worldwide, driving rising rates of cardiovascular disease, fatty liver disease, kidney complications and escalating healthcare costs. What began as a niche class of diabetes medications has evolved into one of the most transformative therapeutic categories in modern medicine, with GLP-1 receptor agonists now reshaping obesity treatment, metabolic care and potentially even neurodegenerative disease management. Against this backdrop, <strong>SureNano Science Ltd.</strong> (CSE: SURE) (OTCQB: SURNF), (<a target="_blank" href="https://www.globenewswire.com/Tracker?data=TxIEcDI7YtwQSV7h41tMHH-Mi0jMbk21NwO5mbPpRIYxKphxg9hCiTXtPNdnIHiGKdtrmEQHPZ4F3mIj7ci4n-EhpMw_js6g6yU0kaihYelzhgCBhtaOTXgXjyQEGBKEXpqtESvHgh35SZCZnFLCBA==" rel="nofollow" http://www.streetinsider.com/Press+Releases/The+Next+Generation+of+the+GLP-1+Revolution+Is+Already+Underway/26465701.html Mon, 11 May 2026 08:30:00 -0400 A.02973684 A.06822034 A.50200193 AMGN LLY NOVOB NVO O.00000313 O.00027089 O.00285735 O.00291573 O.00448140 O.03044482 O.20026344 O.53179545 PFE SURE SURNF http://www.streetinsider.com/Press+Releases/The+Next+Generation+of+the+GLP-1+Revolution+Is+Already+Underway/26465701.html <p>AUSTIN, Texas, May 11, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=447VppT4EXxq_CCLB-sZm4HI-4KfxnaBb_V7jK4mVgmGT9tfMoQV3ndYuiNHZSq62npUt-qcWMUO0BJ2Xmr5OXNkNo1qhbJrjYlg6QNqLhuAm6eUoS5DZ0bZLasNuorJ" rel="nofollow" target="_blank">BioMedWire Editorial Coverage</a>: Obesity and type 2 diabetes mellitus (T2DM) have become two of the most pressing healthcare challenges worldwide, driving rising rates of cardiovascular disease, fatty liver disease, kidney complications and escalating healthcare costs. What began as a niche class of diabetes medications has evolved into one of the most transformative therapeutic categories in modern medicine, with GLP-1 receptor agonists now reshaping obesity treatment, metabolic care and potentially even neurodegenerative disease management. Against this backdrop, <strong>SureNano Science Ltd.</strong> (CSE: SURE) (OTCQB: SURNF), (<a target="_blank" href="https://www.globenewswire.com/Tracker?data=TxIEcDI7YtwQSV7h41tMHH-Mi0jMbk21NwO5mbPpRIYxKphxg9hCiTXtPNdnIHiGKdtrmEQHPZ4F3mIj7ci4n-EhpMw_js6g6yU0kaihYelzhgCBhtaOTXgXjyQEGBKEXpqtESvHgh35SZCZnFLCBA==" rel="nofollow" http://www.streetinsider.com/Press+Releases/The+Next+Generation+of+the+GLP-1+Revolution+Is+Already+Underway/26465701.html Mon, 11 May 2026 08:30:00 -0400 A.02973684 A.06822034 A.50200193 AMGN LLY NOVOB NVO O.00000313 O.00027089 O.00285735 O.00291573 O.00448140 O.03044482 O.20026344 O.53179545 PFE SURE SURNF http://www.streetinsider.com/Press+Releases/The+Next+Generation+of+the+GLP-1+Revolution+Is+Already+Underway/26465701.html <p>AUSTIN, Texas, May 11, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=447VppT4EXxq_CCLB-sZm4HI-4KfxnaBb_V7jK4mVgmGT9tfMoQV3ndYuiNHZSq62npUt-qcWMUO0BJ2Xmr5OXNkNo1qhbJrjYlg6QNqLhuAm6eUoS5DZ0bZLasNuorJ" rel="nofollow" target="_blank">BioMedWire Editorial Coverage</a>: Obesity and type 2 diabetes mellitus (T2DM) have become two of the most pressing healthcare challenges worldwide, driving rising rates of cardiovascular disease, fatty liver disease, kidney complications and escalating healthcare costs. What began as a niche class of diabetes medications has evolved into one of the most transformative therapeutic categories in modern medicine, with GLP-1 receptor agonists now reshaping obesity treatment, metabolic care and potentially even neurodegenerative disease management. Against this backdrop, <strong>SureNano Science Ltd.</strong> (CSE: SURE) (OTCQB: SURNF), (<a target="_blank" href="https://www.globenewswire.com/Tracker?data=TxIEcDI7YtwQSV7h41tMHH-Mi0jMbk21NwO5mbPpRIYxKphxg9hCiTXtPNdnIHiGKdtrmEQHPZ4F3mIj7ci4n-EhpMw_js6g6yU0kaihYelzhgCBhtaOTXgXjyQEGBKEXpqtESvHgh35SZCZnFLCBA==" rel="nofollow" http://www.streetinsider.com/Press+Releases/The+Next+Generation+of+the+GLP-1+Revolution+Is+Already+Underway/26465701.html Mon, 11 May 2026 08:30:00 -0400 A.02973684 A.06822034 A.50200193 AMGN LLY NOVOB NVO O.00000313 O.00027089 O.00285735 O.00291573 O.00448140 O.03044482 O.20026344 O.53179545 PFE SURE SURNF http://www.streetinsider.com/Press+Releases/The+Next+Generation+of+the+GLP-1+Revolution+Is+Already+Underway/26465701.html <p>AUSTIN, Texas, May 11, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=447VppT4EXxq_CCLB-sZm4HI-4KfxnaBb_V7jK4mVgmGT9tfMoQV3ndYuiNHZSq62npUt-qcWMUO0BJ2Xmr5OXNkNo1qhbJrjYlg6QNqLhuAm6eUoS5DZ0bZLasNuorJ" rel="nofollow" target="_blank">BioMedWire Editorial Coverage</a>: Obesity and type 2 diabetes mellitus (T2DM) have become two of the most pressing healthcare challenges worldwide, driving rising rates of cardiovascular disease, fatty liver disease, kidney complications and escalating healthcare costs. What began as a niche class of diabetes medications has evolved into one of the most transformative therapeutic categories in modern medicine, with GLP-1 receptor agonists now reshaping obesity treatment, metabolic care and potentially even neurodegenerative disease management. Against this backdrop, <strong>SureNano Science Ltd.</strong> (CSE: SURE) (OTCQB: SURNF), (<a target="_blank" href="https://www.globenewswire.com/Tracker?data=TxIEcDI7YtwQSV7h41tMHH-Mi0jMbk21NwO5mbPpRIYxKphxg9hCiTXtPNdnIHiGKdtrmEQHPZ4F3mIj7ci4n-EhpMw_js6g6yU0kaihYelzhgCBhtaOTXgXjyQEGBKEXpqtESvHgh35SZCZnFLCBA==" rel="nofollow" http://www.streetinsider.com/Press+Releases/The+Next+Generation+of+the+GLP-1+Revolution+Is+Already+Underway/26465701.html Mon, 11 May 2026 08:30:00 -0400 A.02973684 A.06822034 A.50200193 AMGN LLY NOVOB NVO O.00000313 O.00027089 O.00285735 O.00291573 O.00448140 O.03044482 O.20026344 O.53179545 PFE SURE SURNF http://www.streetinsider.com/Press+Releases/The+Next+Generation+of+the+GLP-1+Revolution+Is+Already+Underway/26465701.html <p>AUSTIN, Texas, May 11, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=447VppT4EXxq_CCLB-sZm4HI-4KfxnaBb_V7jK4mVgmGT9tfMoQV3ndYuiNHZSq62npUt-qcWMUO0BJ2Xmr5OXNkNo1qhbJrjYlg6QNqLhuAm6eUoS5DZ0bZLasNuorJ" rel="nofollow" target="_blank">BioMedWire Editorial Coverage</a>: Obesity and type 2 diabetes mellitus (T2DM) have become two of the most pressing healthcare challenges worldwide, driving rising rates of cardiovascular disease, fatty liver disease, kidney complications and escalating healthcare costs. What began as a niche class of diabetes medications has evolved into one of the most transformative therapeutic categories in modern medicine, with GLP-1 receptor agonists now reshaping obesity treatment, metabolic care and potentially even neurodegenerative disease management. Against this backdrop, <strong>SureNano Science Ltd.</strong> (CSE: SURE) (OTCQB: SURNF), (<a target="_blank" href="https://www.globenewswire.com/Tracker?data=TxIEcDI7YtwQSV7h41tMHH-Mi0jMbk21NwO5mbPpRIYxKphxg9hCiTXtPNdnIHiGKdtrmEQHPZ4F3mIj7ci4n-EhpMw_js6g6yU0kaihYelzhgCBhtaOTXgXjyQEGBKEXpqtESvHgh35SZCZnFLCBA==" rel="nofollow" http://www.streetinsider.com/Press+Releases/The+Next+Generation+of+the+GLP-1+Revolution+Is+Already+Underway/26465701.html Mon, 11 May 2026 08:30:00 -0400 A.02973684 A.06822034 A.50200193 AMGN LLY NOVOB NVO O.00000313 O.00027089 O.00285735 O.00291573 O.00448140 O.03044482 O.20026344 O.53179545 PFE SURE SURNF